Telmisartan has been approved in the European Union and in the Other Countries

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


telmisartan studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
AZA40052/53 IV Telmisartan Therapy for Hypertension in a Primary-Care Setting: A Canadian Observational Study
TELF 4001/AZA30012 IV An open label randomized study of efficacy and safety of telmisartan administered during 12 weeks in combination and as sequential single therapy (TEAM study).
TELF4002/AZA30013 IV Comparison, with self measurements of blood pressure, of residual efficacy of telmisartan and perindopril in mild to moderate essential hypertension (EVERESTE study).
AZA30002 III An open, non-controlled study to investigate the safety and efficacy of 12 to 96 weeks of treatment with telmisartan when administered to patients with hypertension.
AZA30003 III A prospective double-blind, randomised, placebo-controlled, 3 week crossover study to investigate the effects of telmisartan 40mg on arterial compliance and endothelial function in type 2 diabetes subjects with essential hypertension.
AZA30004 III A prospective, double-blind, randomised, placebo-controlled, 3 week cross-over study to investigate the effects of telmisartan on pulse wave velocity and arterial compliance in subjects with isolated systolic hypertension.
AZA30005 III A prospective, randomised, open-label, blinded endpoint (PROBE), parallel group study comparing a one-step response based titration regimen of 12 weeks duration of telmisartan with enalapril in patients with essential hypertension.
AZA30006 III A prospective, randomized, double-blind, parallel group study to compare the adjunctive effect of telmisartan with existing antihypertensive therapy in patients with essential hypertension that is uncontrolled on current therapy.
HAZ30001 III A prospective, randomised, open-label, blinded-endpoint, parallel group study comparing telmisartan plus hydrochlorothiazide with losartan plus hydrochlorothiazide in subjects with essential hypertension.
HAZ30002 III A prospective, randomised, open-label, parallel group study to investigate the effects of 12 months treatment with telmisartan plus hydrochlorothiazide or ramipril plus hydrochlorothiazide on left ventricular mass index in subjects with left ventricular hypertrophy and essential hypertension
TELF 3002/AZA30020 III Acute effects of the Angiotensin 1 receptor blockade, telmisartan 80 mg, on the nitric oxide flow-mediated vasodilation of radial artery, in healthy volunteers
TELT01 (AZA30015) III P.R.O.B.E. (Prospective, Randomized, Open-label, Blinded Endpoint) multicentre, parallel-group study to evaluate the efficacy of telmisartan 40/80 mg vs losartan 50/100 mg in patients with mild/moderate hypertension
TELT03 (AZA30016) III P.R.O.B.E. (Prospective, Randomized, Open label, Blinded Endpoint) multicentre, parallel group study to evaluate the efficacy of telmisartan 40/80 mg vs lisinopril 10/20 mg in the reduction of progressive renal impairment in hypertensive subjects with type 2 diabetes.